Novartis AG (NYSE:NVS) Trend Analysis released that first ever results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies showing AIN457 (secukinumab) demonstrated rapid as well as significant clinical improvements versus placebo in improving the signs and symptoms of psoriatic arthritis. Secukinumab demonstrated significant and sustained efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis in two pivotal studies Novartis AG (NYSE:NVS) stock hit highest price at $94.75, beginning with a price of $94.09 and reported an increase of 0.46% to the closed at $94.38 with a day range of $94.04-$94.75. The total market capitalization remained 228.3 Billion, total volume of 1.07 Million shares held in the session was surprisingly higher than its average volume of 1357.16 shares.Medtronic, Inc. (NYSE:MDT) Trend Analysis released that new data supporting the clinical and economic value of its cardiac resynchronization therapy devices for the treatment of heart failure, comprising a significant reduction in all-cause 30-day readmissions after heart failure hospitalizations. Shares of Medtronic, Inc. (NYSE:MDT) traded at $69.19 by moving up 0.35% with price volatility of 1.19% for a week and 1.41% for a month. Its beta stands at 1.04 times.Exelixis, Inc. (NASDAQ:EXEL) Trend Analysis released that preliminary results from a phase 1 investigator-sponsored examination evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90, in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma. Exelixis, Inc. (NASDAQ:EXEL) stock has highest price of $1.78 in last session, beginning with a price of $1.75 and reported an increase of 1.73% to the closed at $1.76 with a day range of $1.71-$1.78. The stock is going forward its 52-week low with 30.37% and moving down from its 52 week high price with -79.07%.
Hot and Soars Stocks: Novartis AG (NYSE:NVS), Medtronic, Inc. (NYSE:MDT), Exelixis, Inc. (NASDAQ:EXEL)







